NCT00918463View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

May 23, 2011

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

dasatinib

100 mg daily dosing

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT00918463 - A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter